Intellectual Ventures accused NettApp’s MetroCluster Fabric Attached systems of infringing U.S. Patent No. 6,516,442, which covers aspects of symmetric multi-processor types of computer architecture by which multiple processors share a common operating system and memory. Each asserted claim required certain components of the system to “perform error correction of the data in the packets exchanged over the channels.” NettApp asserted that the MetroCluster products, which allow for continuous back-up of data to separate locations, do not satisfy this “error correction” limitation, as the term had been construed. Judge Saris granted NettApp’s motion for summary judgment of non-infringement. She had construed the term to mean “correcting errors in data by at least reconstructing erroneous data,” rejecting Intellectual Ventures proposal that the term be construed broadly enough to encompass the correction of errors using a retry request. The MetroCluster systems break down data packets into sub-packets, to which an error detection code is appended. The system discards data in which an error is detected and then retransmits the data. Once the correct data has been received, the system puts the sub-packets back together into a complete packet. Intellectual Ventures asserts that this re-assembly of the sub-packets into full packets satisfies the “reconstruction” aspect of the limitation; Judge Saris disagreed, however, finding that her construction of the “error correction” limitation unambiguously excluded a system that exclusively addressed errors through a retry procedure. She also noted that the reassembly process utilized by the MetroCluster systems was not a part of handling errors, as such reassembly occurs whether an error is detected or not.
Sonohm accuses Superlogics of infringing two patents, U.S. 6,651,207, related to improved voice quality in cordless communications utilizing frequency hopping, and U.S. 7,106,705, which is directed to methods and systems for transmitting data for multiple services via jointly used physical channels. The ‘207 patent is expired, while the ‘705 patent remains in effect only through May 2021. According to the assignment records of the PTO, Sonohm acquired both patents in September 2019, after the ‘207 patent had expired. Since then, Sonohm has filed seventeen infringement suits involving the two patents, nine of which settled within about six months. The case has been assigned to Judge Burroughs.
Wildlife Acoustics makes bioacoustics monitoring technology used to monitor various animal species around the world. This technology can supplement or replace other, more manpower-intensive monitoring methods. Wildlife’s recorder design allowed for a significant reduction in power usage, enabling the use of much smaller batteries and a smaller and lighter recording device that is considerably easier to pack into remote locations. Wildlife accuses Australia’s Frontier Labs of infringing its U.S. Patent No. 7,782,195, which covers these recording devices, through the sale of competing BAR audio recording devices. Judge O’Toole has been assigned to the case, which was filed by my firm, Lando & Anastasi.
Judge Young granted Stilla’s motion for a 90 day stay of this patent litigation related to droplet digital PCR technology. Bio-Rad accuses Stilla’s Naica™ System of infringement. Stilla sought to stay the case to allow its France-based staff, who are under severe travel and work restrictions, to focus on their development of a COVID-19 diagnostic test kit that uses the Naica™ System. Deciding to prolong a litigation is not the norm for Judge Young, who in December refused to accept a joint schedule that proposed trying the case in mid-February, 2021, stating that the case would go to trial no later than January 2021. The pandemic changes things, however, and the stay was granted just three days after it was sought, despite Stilla’s notice that Bio-Rad opposed the stay.
Judge Talwani denied Ice River’s motion to stay pending resolution of a third party’s petition for inter partes review of all of the claims asserted in this case. She indicated that, as inter partes review had not yet been instituted, she was denying the motion without prejudice to renew should the review move forward. While not expressed in her brief order, Judge Talwani was likely influenced by the fact that the case is in the middle of what appears to be contentious discovery and with a Markman hearing scheduled for April. Further, Ice River did not agree to be bound by the outcome of the IPR, should it be instituted (as the IPR was requested by a third party, Ice River would not be precluded from reasserting issues that were or reasonably could have been raised in the way that the third party would).
SynKloud accuses Nuance of infringing U.S. Patent No. RE 44,248, directed towards enhanced voice recognition technologies. The ‘248 patent is a reissue of U.S. 7,689,416. SynKloud asserts that certain of Nuance’s Dragon products infringe through allowing users to transfer voice model files between computers, enhancing the speech recognition accuracy in the destination computer. SynKloud first notified Nuance of the ‘248 patent in April of 2015, but Nuance continued to sell the accused Dragon products. SynKloud specifically pleads that neither it nor any predecessors in interest have made, sold or licensed any products covered by the ‘248 patent and thus requiring marking. SynKloud claims direct, induced and contributory infringement. Judge Saris has the case.
Biogen, along with the University of Zurich, accuses New York-based Creative Biolabs of infringing U.S. Patent No. 8,906,367. The patent is said to cover an antibody, Aducanumab, that Biogen is investigating as a treatment for early Alzheimer’s disease. Biogen licensed the antibody from a Swiss biotech company, Neurimmune Therapeutics, who had itself licensed the antibody and accompanying intellectual property from the University of Zurich. The antibody was developed from antibodies in healthy, aged donors who did not have Alzheimer’s, under the theory that these individuals’ immune systems had successfully resisted the disease, and the treatment has reduced the plaques that are a marker of the disease in animal studies. Biogen is presently working in collaboration with pharmaceutical company Eisai in clinical development and commercialization of the antibody, which is also known by the widely-used designation “BIIB037,” and is currently seeking regulatory approval for its use, currently back in trials after having previously been pulled. In addition to patent infringement, Biogen asserts that Creative Biolabs infringes Biogen’s trademark rights in the “BIIB037” alternate designation, which Biogen believes will cause confusion or mistake as to the origin, sponsorship or approval of Creative Biolabs’ aducanumab products. Biogen also asserts violation of 93A. The case is with Magistrate Judge Cabell.